申请人:Knust Henner
公开号:US20100197697A1
公开(公告)日:2010-08-05
The present invention relates to a compounds of formula I
wherein
A, Ar
1
, Ar
2
, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, m, n, o, p, s, t, and u are as defined herein or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
本发明涉及一种公式I的化合物,其中A,Ar1,Ar2,R1,R2,R3,R4,R5,R6,m,n,o,p,s,t和u如此定义,或其药物活性盐,外消旋体混合物,对映体,光学异构体或其互变异构体形式。所述化合物是高潜力的NK-3受体拮抗剂,用于治疗抑郁症,疼痛,精神病,帕
金森病,精神分裂症,焦虑症和注意力缺陷多动障碍(ADHD)。